ReShape Lifesciences (RSLS) Q3 2024 earnings summary

Executive summary

• Revenue increased 16.6% sequentially and 6.4% year-over-year in Q3 2024, marking the third consecutive quarter of growth, driven by focused marketing despite GLP-1 competition.

• Operating expenses for the first nine months of 2024 were reduced by over 40% compared to last year, supporting improved profitability.

• Net loss for Q3 2024 was $1.6 million, a significant improvement from $3.5 million in Q3 2023, reflecting cost reductions and operational efficiencies.

• The company completed the early launch phase of Lap-Band 2.0 FLEX, received Health Canada approval, and secured a $241,000 NIH grant for the DBSN device.

• Entered into a merger agreement with Vyome Therapeutics and an asset sale to Biorad, with the latter valued at $5.16 million in cash.

Financial highlights

• Q3 2024 revenue was $2.3 million, up 16.6% sequentially and 6.4% year-over-year; nine-month revenue was $6.2 million, down 7.4% year-over-year.

• Gross profit for Q3 2024 was $1.4 million, with a gross margin of 62.8%, up from 59.8% in Q3 2023.

• Net loss for Q3 2024 was $1.6 million, improved from $3.5 million in Q3 2023.

• Sales and marketing expenses for Q3 2024 fell about 60% year-over-year due to a shift to digital campaigns and reduced staffing.

• Cash and cash equivalents at September 30, 2024, were $0.8 million, with net working capital of $1.3 million.

Outlook and guidance

• The company is optimistic about Lap-Band 2.0 FLEX's market potential, especially as GLP-1 adoption plateaus and more patients seek minimally invasive options.

• The merger with Vyome and asset sale to Biorad are expected to be critical for future operations, liquidity, and shareholder value.

• Management is focused on a metrics-driven, scalable business model with digital lead generation and ongoing cost reduction initiatives.

• If additional financing is not secured or the transactions do not close, the company may need to delay, limit, or terminate development and commercialization efforts.